Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test

Chris Parker appointed CEO and Board Member

Jarret Glasscock, founder and CEO, transitions to Chief Technology Officer (CTO), Board Member, and President

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been named CEO and Board Member to lead Cofactor’s plan to bring precision medicine to immunotherapy. Simultaneously, the company announced that Jarret Glasscock, scientist and Cofactor Genomics founder, will transition into the role of President, Chief Technology Officer (CTO), and Board Member.

Parker joins Cofactor following the 2024 Medicare coverage of Cofactor’s OncoPrism, a test identifying cancer patients who may benefit from immune checkpoint inhibitor immunotherapy. Under Parker’s leadership, the company will accelerate its commercialization efforts to ensure broad access to its immunotherapy precision medicine solution.

“Cofactor has been on a mission, leveraging the greatest technological advancements of our generation to create a unique technology bringing precision medicine to immunotherapy,” said Jarret Glasscock, Cofactor’s President, founder, and former CEO. “This year marks a new chapter at Cofactor, as we transition from R&D to the commercial phase of development in bringing OncoPrism to patients. Chris brings to Cofactor decades of experience and leadership in some of the most successful biotech and diagnostic organizations in our industry. Given Cofactor’s recent clinical, regulatory, and reimbursement milestones, I look forward to partnering with Chris to continue on this trajectory and ensure broad patient access to a solution desperately needed in oncology.”

Chris Parker has spent nearly three decades leading teams bringing breakthrough technologies to the forefront of biotechnology and diagnostics. Prior to joining Cofactor Genomics, Parker held executive leadership roles at Affymetrix, Cellular Dynamics, Exact Sciences, Adela, and numerous board positions at companies at various stages during his career.

“As the company moves into this next exciting phase to bring much needed clarity to help physicians better identify patients that will benefit from immunotherapies, I am honored that Jarret and the Board of Directors have the confidence in me to lead this next chapter. I look forward to building on the great work already accomplished by complementing Jarret’s scientific leadership and bringing a strong commercial focus to the company. Cofactor’s OncoPrism technology represents a solution for immunotherapies currently being prescribed to cancer patients, but also may hold the key to practicing precision medicine in many of the therapies currently under development.”

This announcement follows Q4/2024 announcements of Medicare Coverage of Cofactor’s OncoPrism in Head and Neck Cancer Patients, clinical validation of the test in Non-Small Cell Lung cancer patients, and publication of the first clinical results from Cofactor’s national clinical trial (PREDAPT), which showed a 3X increase in specificity over PD-L1 and a 4X increase in specificity over TMB (the two most widely used clinical tests striving to provide treatment guidance for patients being considered for immunotherapy). While commercialization ramps in the indications already in clinical use (HNSCC and NSCLC), the company will continue on its current course of aggressive clinical evidence expansion, evaluating OncoPrism’s performance across 11 solid tumor cancers that are the focus of the PREDAPT multi-site clinical trial (NCT04510129).

About Cofactor:

Cofactor Genomics is a commercial stage diagnostics company that bridges the precision medicine gap by decoding RNA to solve the biggest problems in healthcare. It accomplishes this by unlocking RNA’s use as a transformational barometer of health through its PRISM database of patented Health Expression Models (HEMs). HEMs are a departure from common and often uninformative gene mutation panel tests. They represent the latest advancements in machine learning and RNA, transforming billions of biological RNA data points into Cofactor’s high-dimensional RNA models of biology, disease, and therapy response.

Cofactor’s pioneering work in RNA modeling has been published in The Journal of ImmunoTherapy of Cancer, The Journal of Molecular Diagnostics, and recognized by Nature Scientific Reports as breakthrough work in cancer. Cofactor is supported and partnered with 38 healthcare systems, representing 20% of US healthcare. Cofactor’s OncoPrism is CAP/CLIA-validated and Medicare-approved. Learn more from www.cofactorgenomics.com and LinkedIn.